Evidence map›Paper›PMID 35162954›Full record

ArticleInternational journal of molecular sciences2022

Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer.

Mariana Nunes, Francisca Pacheco, Ricardo Coelho, Dina Leitão, Sara Ricardo, Leonor David

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mariana NunesDifferentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.ORCID 0000-0002-4733-5778
Francisca PachecoDifferentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.ORCID 0000-0003-0384-4500
Ricardo CoelhoOvarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, CH-4031 Basel, Switzerland.
Dina LeitãoDepartment of Pathology, Medical Faculty of the University of Porto (FMUP), 4200-319 Porto, Portugal.
Sara RicardoDifferentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.ORCID 0000-0003-4091-2226
Leonor DavidDifferentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal.ORCID 0000-0003-4207-9258
Universidade do Porto · PTUniversity of Basel · CH

Funding

Fundação para a Ciência e Tecnologia 2020.04720.BDFundação para a Ciência e Tecnologia PTDC/MEC-ONC/29503/2017HOPE: Improving ovarian cancer patients' survival Donation from an ovarian cancer patient
6 · The paper itself

Abstract

Mesothelin (MSLN) overexpression (OE) is a frequent finding in ovarian carcinomas and increases cell survival and tumor aggressiveness. Since cancer stem cells (CSCs) contribute to pathogenesis, chemoresistance and malignant behavior in ovarian cancer (OC), we hypothesized that MSLN expression could be creating a favorable environment that nurtures CSCs. In this study, we analyzed the expression of MSLN and CSC markers SOX2 and ALDH1 by immunohistochemistry (IHC) in different model systems: primary high-grade serous carcinomas (HGSCs) and OC cell lines, including cell lines that were genetically engineered for MSLN expression by either CRISPR-Cas9-mediated knockout (Δ) or lentivirus-mediated OE. Cell lines, wild type and genetically engineered, were evaluated in 2D and 3D culture conditions and xenografted in nude mice. We observed that MSLN was widely expressed in HGSC, and restricted expression was observed in OC cell lines. In contrast, SOX2 and ALDH1 expression was limited in all tissue and cell models. Most importantly, the expression of CSC markers was independent of MSLN expression, and manipulation of MSLN expression did not affect CSC markers. In conclusion, MSLN expression is not involved in driving the CSC phenotype.

Indexed as

Aldehyde Dehydrogenase 1 FamilyAnimalsBiomarkers, TumorCell Line, TumorCystadenocarcinoma, SerousFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMesothelinMiceNeoplastic Stem CellsOvarian NeoplasmsRetinal DehydrogenaseRetrospective StudiesSOXB1 Transcription FactorsAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorMesothelinMSLN protein, humanRetinal DehydrogenaseSOX2 protein, humanSOXB1 Transcription FactorsALDH1cancer stem cellshigh-grade serous carcinomamesothelinSOX2

Identifiers

PMID35162954
PMCPMC8834752
OpenAlexW4206189812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.